Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3SLC6A2
The experimentally established mechanism targets of Racephedrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.96 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.96 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.54 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | HBB | P68871 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.96 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.96 |
| ▸ | RGS12 | O14924 | 1/20 | 0.96 |
| ▸ | GLA | P06280 | 1/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.96 |
| ▸ | PKM | P14618 | 1/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.96 |
| ▸ | HTR2A | P28223 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pseudoephedrine SCHEMBL33285 | 1.00 | KMT2A (1.00) | KMT2AMEN1HBBADRA2CCYP2D6 | |
| Ephedrine SCHEMBL22822 | 1.00 | KMT2A (1.00) | KMT2AMEN1HBBADRA2CCYP2D6 | |
| Pseudoephedrine SCHEMBL118099 | 1.00 | KMT2A (1.00) | KMT2AMEN1HBBADRA2CCYP2D6 | |
| Racephedrine SCHEMBL28253267 | 1.00 | KMT2A (1.00) | KMT2AMEN1HBBADRA2CCYP2D6 | |
| Racephedrine SCHEMBL22824 | 1.00 | KMT2A (1.00) | KMT2AMEN1HBBADRA2CCYP2D6 | |
| Racephedrine SCHEMBL22823 | 1.00 | KMT2A (1.00) | KMT2AMEN1HBBADRA2CCYP2D6 | |
| Racephedrine SCHEMBL27878452 | 0.98 | KMT2A (0.96) | KMT2AMEN1HBBADRA2CCYP2D6 | |
| Racephedrine SCHEMBL9413942 | 0.98 | KMT2A (0.96) | KMT2AMEN1HBBADRA2CCYP2D6 | |
| Pseudoephedrine SCHEMBL17004001 | 0.98 | KMT2A (0.96) | KMT2AMEN1HBBADRA2CCYP2D6 | |
| Racephedrine SCHEMBL8098202 | 0.98 | CYP2D6 (1.00) | KMT2AMEN1HBBADRA2CCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024040267-A2 | DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF | MITOKININ, INC. (US) | 2024-02-22 | — | — | WO | claimed |
| US-20190145960-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2019-05-16 | — | — | US | claimed |
| EP-3470536-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | The J. David Gladstone Institutes (US) | 2019-04-17 | — | — | EP | claimed |
| US-10184933-B2 | Compositions, systems and methods for gene expression noise drug screening and uses thereof | The J. David Gladstone Industries (US) | 2019-01-22 | — | — | US | claimed |
| US-20160245796-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | THE J. DAVID GLADSTONE INSTITUTES (US) | 2016-08-25 | — | — | US | claimed |
| EP-3052662-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | The J. David Gladstone Institutes (US) | 2016-08-10 | — | — | EP | claimed |
| WO-2015051035-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | THE J. DAVID GLADSTONE INSTITUTES (US) | 2015-04-09 | — | — | WO | claimed |
| JP-7165569-A | — | — | None | — | — | JP | disclosed |
| US-20250049722-A1 | TRIPULSE RELEASE STIMULANT FORMULATIONS | Cingulate Therapeutics LLC (US) | 2025-02-13 | — | — | US | disclosed |
| EP-3261625-B1 | TRIPULSE RELEASE STIMULANT FORMULATIONS | Cingulate Therapeutics LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| WO-2024040267-A2 | DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF | MITOKININ, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20230121531-A1 | TRIPULSE RELEASE STIMULANT FORMULATIONS | Cingulate Therapeutics LLC (US) | 2023-04-20 | — | — | US | disclosed |
| CN-110642721-B | Preparation method of selegiline hydrochloride | 安徽贝克生物制药有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-1278853-A | Gel adhesive, adhesive material containing gel adhesive and adhesive pharmaceutical preparation | TEIJIN LTD (JP) | 2001-01-03 | — | — | CN | disclosed |
| WO-2000059481-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000059479-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | disclosed |
| CN-1054120-C | Ephedrine extracting process | UNIV QINGHUA (CN) | 2000-07-05 | — | — | CN | disclosed |
| CN-1132740-A | Ephedrine extracting process | UNIV QINGHUA (CN) | 1996-10-09 | — | — | CN | disclosed |
| JP-H07165569-A | AMELIORANT FOR CEREBRAL FUNCTION | TSUMURA & CO | 1995-06-27 | — | — | JP | disclosed |
| CN-1043319-A | New amine and uses thereof | MITSUI PHARMACEUTICALS (JP) | 1990-06-27 | — | — | CN | disclosed |